Spatial transcriptomic analysis of Sonic Hedgehog Medulloblastoma identifies that the loss of heterogeneity and promotion of differentiation underlies the response to CDK4/6 inhibition
Tuan VoiD, Brad BaldersoniD, Kahli JonesiD, Guiyan NiiD, Joanna CrawfordiD, Amanda MillariD, Elissa TolsoniD, Matthew SingletoniD, Onkar MulayiD, Shaun B. Walters, Marija KojiciD, Thomas RobertsoniD, Dharmesh Dinesh BhuvaiD, Melissa J. DavisiD, Brandon J. WainwrightiD, Quan Hoang NguyeniD, Laura A. GenovesiiD
Abstract
BackgroundMedulloblastoma (MB) is a malignant tumour of the cerebellum which can be classified into four major subgroups based on gene expression and genomic features. Single cell transcriptome studies have defined the cellular states underlying each MB subgroup, however the spatial organisation of these diverse cell states and how this impacts response to therapy remains to be determined. MethodsHere, we used spatially resolved transcriptomics to define the cellular diversity within a sonic hedgehog (SHH) patient-derived model of MB and identify how cells specific to a transcriptional state or spatial location are pivotal in responses to treatment with the CDK4/6 inhibitor, Palbociclib. We integrated spatial gene expression with histological annotation and single cell gene expression data from MB, developing a analysis strategy to spatially map cell type responses within the hybrid system of human and mouse cells and their interface within an intact brain tumour section. ResultsWe distinguish neoplastic and non-neoplastic cells within tumours and from the surrounding cerebellar tissue, further refining pathological annotation. We identify a regional response to Palbociclib, with reduced proliferation and induced neuronal differentiation in both treated tumours. Additionally, we resolve at a cellular resolution a distinct tumour interface where the tumour contacts neighbouring mouse brain tissue consisting of abundant astrocytes and microglia and continues to proliferate despite Palbociclib treatment. ConclusionsOur data highlight the power of using spatial transcriptomics to characterise the response of a tumour to a targeted therapy and provide further insights into the molecular and cellular basis underlying the response and resistance to CDK4/6 inhibitors in SHH MB.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 23
- FWCI
- 2.04
- Field percentile
- top 12%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Spatial pharmaco-multiomics reveals drug distribution, metabolic niches, and spatially constrained resistance in medulloblastoma
Tuan Vo, Cedric S. Cui, … Quan Hoang Nguyen·bioRxiv·Jan 27, 2026
- Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity with High-Density Progenitor Cell Regions Correlating with High-Risk Disease
Franklin Chien, Marina E. Michaud, … Manoj K. Bhasin·JCO Precision OncologyPeer-reviewed·Oct 1, 2026
- Sonic hedgehog medulloblastoma cells in co-culture with cerebellar organoids converge towards in vivo malignant cell states
Max J. van Essen, Alina Nicheperovich, … John Jacob·Neuro-Oncology AdvancesPeer-reviewed·Dec 13, 2024
- Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib
C. Lim, T. Dismuke, … M. Sokolsky·bioRxiv·Jun 9, 2021
- Spatial and temporal transcriptomics of SHH-medulloblastoma with chromothripsis identifies multiple genetic clones that resist to treatment and lead to relapse
I. Kats, H. S. Schreiber, … A. Ernst·bioRxiv·Mar 3, 2023
- Cell-state plasticity drives heterogeneity in Group 3/4 medulloblastoma
Piyush K. Joshi, Patricia Benites Goncalves da Silva, … Lena M. Kutscher·bioRxiv·Feb 9, 2024